Cited by 231RNA Interference and Gene DeliveryRNA and protein synthesis mechanismsMolecular Biology Techniques and Applications

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Cap 1 Messenger RNA Synthesis with Co‐transcriptional CleanCap ® Analog by In Vitro Transcription

Open access

Henderson, Jordana M., Ujita, Andrew, Hill, Elizabeth, Yousif‐Rosales, Sally, Smith, Cory, Ko, Nicholas, McReynolds, Taylor, Cabral, Charles R., Escamilla‐Powers, Julienne R., Houston, Michael E.·2021·Current Protocols

DOI 10.1002/cpz1.39

Open this paper in CoChat — free account Open PDF

Abstract

Synthetic messenger RNA (mRNA)−based therapeutics are an increasingly popular approach to gene and cell therapies, genome engineering, enzyme replacement therapy, and now, during the global SARS‐CoV‐2 pandemic, vaccine development. mRNA for such purposes can be synthesized through an enzymatic in vitro transcription (IVT) reaction and formulated for in vivo delivery. Mature mRNA requires a 5′‐cap for gene expression and mRNA stability. There are two methods to add a cap in vitro: via a two‐step multi‐enzymatic reaction or co‐transcriptionally. Co‐transcriptional methods minimize reaction steps and enzymes needed to make mRNA when compared to enzymatic capping. CleanCap ® AG co‐transcriptional capping results in 5 mg/ml of IVT with 94% 5′‐cap 1 structure. This is highly efficient compared to first‐generation cap analogs, such as mCap and ARCA, that incorporate cap 0 structures at lower efficiency and reaction yield. This article describes co‐transcriptional capping using TriLink Biotechnology's CleanCap ® AG in IVT. © 2021 The Authors. This article was corrected on 22 November 2021 and 26 July 2022 . See the end of the full text for details. Basic Protocol 1 : IVT with CleanCap Basic Protocol 2 : mRNA purification and analysis

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cpz1.39

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Purification of Biologically Active Globin Messenger RNA by Chromatography on Oligothymidylic acid-Cellulose
Aviv, H., & Leder, P. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.6.1408 · Cited by 6,636
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
mRNA capping: biological functions and applications
Ramanathan, A., Robb, G. B., & Chan, S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw551 · Cited by 961
Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569

Flagged first, then by citations

Show all 38 references

Research works printed but not linked: 1

Green M. R., 2019, Isolation of poly(A)+ messenger RNA using magnetic oligo(dT) beads, Cold Spring Harbor Protocols, 2019

Sorted by citations

Items 101–200 of 231

Urea supplementation improves mRNA in vitro transcription by decreasing both shorter and longer RNA byproducts
Combes, F., Pettersson, F. J., Thanh-Huong, B., Molska, A., Komissarov, A., Parot, J., & Borgos, S. E. (2024) · RNA Biology · doi:10.1080/15476286.2024.2321764 · Cited by 12
Comprehensive chromatographic assessment of forced degraded in vitro transcribed mRNA
Dayeh, D. M., Cika, J., Moon, Y., Henderson, S., Grandi, D. D., Fu, Y., Muthusamy, K., Palackal, N. T., Ihnat, P. M., & Pyles, E. A. (2024) · Journal of Chromatography A · doi:10.1016/j.chroma.2024.464885 · Cited by 11
In vivo demonstration of enhanced mRNA delivery by cyclic disulfide-containing lipid nanoparticles for facilitating endosomal escape
Kimura, S., Okada, K., Matsubara, N., Lyu, F., Tsutsumi, S., Kimura, Y., Hashiya, F., Inagaki, M., Abe, N., & Abe, H. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00084j · Cited by 15
Omicron‐specific mRNA vaccine induced cross‐protective immunity against ancestral SARS‐CoV‐2 infection with low neutralizing antibodies
Shen, K., Yang, C., Chen, C., Ho, H., Chiu, F., Huang, C., Liao, H., Hsu, C., Yu, G., Liao, C., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28370 · Cited by 10
Coding Therapeutic Nucleic Acids from Recombinant Proteins to Next-Generation Vaccines: Current Uses, Limitations, and Future Horizons
Harisa, G. I., Faris, T. M., Sherif, A. Y., Alzhrani, R. F., Alanazi, S. A., Kohaf, N. A., & Alanazi, F. K. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00821-z · Cited by 11
Effective Synthesis of High-Integrity mRNA Using In Vitro Transcription
He, W., Zhang, X., Zou, Y., Li, J., Wang, C., He, Y.-C., Jin, Q., & Ye, J. (2024) · Molecules · doi:10.3390/molecules29112461 · Cited by 13
The mRNA-Based Innovative Strategy: Progress and Challenges
Zhou, H., Wei, D., Chen, Z., Chen, H., Dong, C., Cai, W., Wang, J., Liu, X., Li, Y., Yang, Y., et al. (2026) · Nano-Micro Letters · doi:10.1007/s40820-025-01906-x · Cited by 17
Nanopore direct RNA sequencing and the epitranscriptome: Advances in mapping native RNA landscapes
Zhang, T., Li, J., Tang, C., Wu, Y., Wu, H., Xi-Tong, Z., Luo, Z., Qin, H., Ding, L., Zeng, Y., et al. (2026) · iMeta · doi:10.1002/imt2.70136 · Cited by 17
Cell Reprogramming and Differentiation Utilizing Messenger RNA for Regenerative Medicine
Inagaki, M. (2023) · Journal of Developmental Biology · doi:10.3390/jdb12010001 · Cited by 11
Quality by Digital Design for Developing Platform RNA Vaccine and Therapeutic Manufacturing Processes
Nair, A., Loveday, K. A., Kenyon, C., Qu, J., & Kis, Z. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_16 · Cited by 11
Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations
Phan, T. X., Fan, D., & Melstrom, L. G. (2024) · Current Oncology · doi:10.3390/curroncol31090361 · Cited by 9
Flow-NMR as a Process-Monitoring Tool for mRNA IVT Reaction
Sarkar, A., Dong, G., Quaglia-Motta, J., & Sackett, K. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.11.021 · Cited by 8
BioNTech/Pfizer (BNT162b2) COVID-19 mRNA vaccine: manufacturing, immunogenicity, efficacy and safety
Alkhalil, E., Jarad, B., Saleh, T. A., Aldarwish, W., & Joujeh, D. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.292 · Cited by 8
Therapeutic Application of mRNA for Genetic Diseases
Schürmann, P. J. L., Vriesman, S. V. B., Castro-Alpízar, J., Kooijmans, S. A. A., Nieuwenhuis, E. E. S., Schiffelers, R. M., & Fuchs, S. A. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70019 · Cited by 9
Towards mRNA therapeutics 2.0
Chien, K. R., Foo, K. S., & Witman, N. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01459-7 · Cited by 12
Mobile On Demand COVID-19 Vaccine Production Units for Developing Countries
Fahr, S. R., Peña‐Benavides, S. A., Thiel, L., Sengoba, C., Karacasulu, K., Ihling, N., Sosa‐Hernández, J. E., Gilleskie, G. L., Woodley, J. M., Parra‐Saldívar, R., et al. (2022) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.2c01217 · Cited by 8
Reverse vaccinology-based design of multivalent multiepitope mRNA vaccines targeting key viral proteins of Herpes Simplex Virus type-2
Suneesh, N. S., Dhotre, K., Mahajan, P., Dass, D., Banerjee, A., Siddiqi, N. J., Malik, A., Joshi, M., Khan, A. A., Nema, V., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1586271 · Cited by 7
An immunoinformatics approach in designing high-coverage mRNA multi-epitope vaccine against multivariant SARS-CoV-2
Giri-Rachman, E. A., Kurnianti, A. M. F., Rizarullah, R., Setyadi, A. H., Artarini, A., Tan, M. I., Riani, C., Natalia, D., Aditama, R., & Nugrahapraja, H. (2025) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2025.100524 · Cited by 9
Mesenchymal stem cell engineering by ARCA analog-capped mRNA
Andrzejewska, A., Grzela, R., Stankiewicz-Drogoń, A., Rogujski, P., Nagaraj, S., Darżynkiewicz, E., Łukomska, B., & Janowski, M. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.07.006 · Cited by 7
Future Perspectives for the Identification and Sequencing of Nicotinamide Adenine Dinucleotide-Capped RNAs
Möhler, M., & Jäschke, A. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00446 · Cited by 8
Recombinant T7 RNA polymerase production using ClearColi BL21(DE3) and animal-free media for in vitro transcription
Liang, Q., Tu, B., & Cui, L. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12939-w · Cited by 8
On‐column capping of poly dT media‐tethered mRNA accomplishes high capping efficiency, enhanced mRNA recovery, and improved stability against RNase
Che, S., Xue, F., Li, Z., Su, Z. G., Ma, G., Li, Z., Yu, A., Liu, M., & Zhang, S. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28560 · Cited by 6
Physicochemical and functional assessment of messenger RNA 5′Cap-end impurities under forced degradation conditions
Hutchinson, J., Schweikart, F., Shannon, R., Murthy, A., Bates, S. M., Leone, S., Nissan, T. A., Sideris, D., Lal, C., Button, J., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102570 · Cited by 6
The role of excipients in lipid nanoparticle metabolism: implications for enhanced therapeutic effect
Knaggs, K. L. M., Sun, Y., Walz, B. A., Pang, J., & Khan, O. F. (2025) · Therapeutic Delivery · doi:10.1080/20415990.2025.2506977 · Cited by 7
A modular vaccine platform for optimized lipid nanoparticle mRNA immunogenicity
Fang, Z., Monteiro, V. S., Oh, C., Janabi, K. A., Romero, L., Ahsan, N., Yang, L., Peng, L., DiMaio, D., Lucas, C. G. D. O., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01478-6 · Cited by 6
Enhancing cap-independent translation of linear mRNA
Golojuch, S., Largey, B., El-Sagheer, A. H., & Brown, T. P. (2025) · Nature Communications · doi:10.1038/s41467-025-64257-6 · Cited by 6
mRNA Manufacturing and Single‐use Technology – A Perfect Liaison
Grilo, A. L., & Schmidhalter, D. R. (2022) · Chemie Ingenieur Technik · doi:10.1002/cite.202200147 · Cited by 7
Nonreplicating synthetic mRNA vaccines: A journey through the European (Journal of Immunology) history
Pascolo, S. (2023) · European Journal of Immunology · doi:10.1002/eji.202249941 · Cited by 6
mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond
Prakash, S. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00849-1 · Cited by 6
PCR-generated DNA templates enable efficient, rapid, and cost-effective mRNA synthesis
Kumar, N., Hazell, N. C., Bei, J., Nguyen, T. K., & Hu, H. (2025) · Methods · doi:10.1016/j.ymeth.2025.08.007 · Cited by 5
High-efficiency editing in hematopoietic stem cells and the HUDEP-2 cell line based on in vitro mRNA synthesis
Papaioannou, N. Y., Patsali, P., Naiisseh, B., Papasavva, P. L., Koniali, L., Kurita, R., Nakamura, Y., Christou, S., Sitarou, M., Mussolino, C., et al. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1141618 · Cited by 5
Sequence simplification of antigen coding IVT mRNA allows accelerated synthetic DNA template generation and epitope immunogenicity validation
Esprit, A., Autaers, D., Aernout, I., Lentacker, I., Pascolo, S., Thielemans, K., Breckpot, K., & Franceschini, L. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102591 · Cited by 6
Towards T7 RNA polymerase (T7RNAP)-based expression system in yeast: challenges and opportunities
Moreno, D. S., Qimron, U., Azeredo, J., & Domingues, L. (2022) · Bioengineered · doi:10.1080/21655979.2023.2180579 · Cited by 5
Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment
Tabasi, H., Mollazadeh, S., Fazeli, E., Abnus, K., Taghdisi, S. M., Ramezani, M., & Alibolandi, M. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04597-5 · Cited by 5
Future prospects in mRNA vaccine development
Mbatha, L. S., Akinyelu, J., Maiyo, F., & Kudanga, T. (2023) · Biomedical Materials · doi:10.1088/1748-605x/aceceb · Cited by 7
A (RP)UHPLC/UV analytical method to quantify dsRNA during the mRNA vaccine manufacturing process
Rosa, S. S., Zhang, S., Sari, Y., & Marques, M. P. C. (2024) · Analytical Methods · doi:10.1039/d4ay00560k · Cited by 6
Quantitative Profiling of Human Translation Initiation Reveals Regulatory Elements that Potently Affect Endogenous and Therapeutically Modified mRNAsPreprint
Lewis, C. J. T., Xie, L., Bhandarkar, S., Jin, D., Abdallah, K., Draycott, A. S., Chen, Y., Thoreen, C. C., & Gilbert, W. V. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.28.582532 · Cited by 5
Engineering Anti-Tumor Immunity: An Immunological Framework for mRNA Cancer Vaccines
Roy, O., & Anderson, K. S. (2025) · Vaccines · doi:10.3390/vaccines13121222 · Cited by 5
Navigating molecular therapies: The emerging role of mRNA in treating inherited metabolic diseases
Castro-Alpízar, J., Lenderink, M. J., Nieuwenhuis, E. E. S., Kooijmans, S. A. A., & Fuchs, S. A. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109698 · Cited by 4
In vivo CAR-T therapy: from molecular design to precision delivery
Li, H., Wen, W., Zhao, X., & Liang, G. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04232-5 · Cited by 4
Quality Control of mRNA Vaccines by Synthetic Ribonucleases: Analysis of the Poly‐A‐Tail
Zellmann, F., Schmauk, N., Murmann, N. S., Böhm, M., Schwenger, A., & Göbel, M. (2024) · ChemBioChem · doi:10.1002/cbic.202400347 · Cited by 5
The Recent Research Progress of the Tumor mRNA Vaccine
Zhao, H., Li, M., Zhou, J., Hu, L., Lu, S., & Li, P. (2024) · Vaccines · doi:10.3390/vaccines12101167 · Cited by 5
Synthesis of hydrophobic-tagged 2′-deoxy-modified cap analogs and its effect on mRNA translation
Meng, Z., Nakashima, Y., Inagaki, M., Li, Z., Acharyya, S., Hashiya, F., Abe, N., Kimura, Y., & Abe, H. (2025) · Bulletin of the Chemical Society of Japan · doi:10.1093/bulcsj/uoaf006 · Cited by 4
Established Protocols for cRNA Expression and Voltage-Clamp Characterization of the P2X7 Receptor in Xenopus laevis Oocytes
Schmalzing, G., & Markwárdt, F. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2384-8_9 · Cited by 4
Detection of residual T7 RNA polymerase used in mRNA in vitro transcription by Simple Western
Shieh, Y., Swartz, A. R., & Rustandi, R. R. (2024) · Electrophoresis · doi:10.1002/elps.202400044 · Cited by 4
The P(III)‐Amidite Based Synthesis of Stable Isotope Labeled mRNA‐Cap‐Structures Enables their Sensitive Quantitation from Brain Tissue
Ripp, A., Krämer, M., Barth, V., Moser, P., Haas, T., Singh, J., Huck, T., Gleue, L., Friedland, K., Helm, M., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202414537 · Cited by 6
Design and Expression of Fasciola hepatica Multiepitope Constructs Using mRNA Vaccine Technology
Sánchez‐Montejo, J., Strilets, T., Manzano-Román, R., López‐Abán, J., García-Blanco, M. A., Vicente, B., & Muro, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031190 · Cited by 5
Synthesis of Nucleic Acids
Watts, J. K., & Gait, M. J. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781837671328-00279 · Cited by 4
Novel trinucleotide mRNA capping reagents: improved synthetic route and efficient cotranscriptional incorporation in mRNA
Xu, C., Cousins, R., Ilichev, I., Ceja, J. A. O., Ludford, P. T., Begoyan, V., Turner, M., dos Santos, M. C. L. G., Vo, C., Rezvani, F., et al. (2025) · RNA · doi:10.1261/rna.080634.125 · Cited by 3
Self-citation
Single-step recovery of mRNA via multimodal chromatography to advance vaccine manufacturing
Rosa, S. S., Stibbs, D. J., Couto, P. S., Prazeres, D. M. F., Azevedo, A. M., Bracewell, D. G., & Marques, M. P. C. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.466610 · Cited by 3
Beginning of a new era of synthetic messenger RNA therapeutics: Comprehensive insights on mRNA drug design, development and applications
Heendeniya, S. N., Chen, S., Bhatti, S. H., Zahra, Q. U. A., Rahimizadeh, K., Poudel, B. H., Wilton, S. D., & Veedu, R. N. (2025) · Experimental Biology and Medicine · doi:10.3389/ebm.2025.10784 · Cited by 3
The 5′ Cap Epitranscriptome and Beyond: Natural and Engineered 5′ Cap Modifications for Optimizing mRNA Therapeutics and Functional Studies
Dahm, G. C., Pieper, M., Schepers, H., & Rentmeister, A. (2026) · ChemMedChem · doi:10.1002/cmdc.202500826 · Cited by 6
An engineered linear cap-independent mRNA vaccine with intrinsic adjuvanticity induces potent anti-tumor immunity in mice
Yu, H., Yang, Y., Lin, P., Liu, C., Wen, Y., Huang, Z., Fang, Z., Hu, Z., & St, H. (2026) · Nature Communications · doi:10.1038/s41467-026-69972-2 · Cited by 3
Non-viral and mRNA-based strategies for next-generation CAR-T cell therapy
Wang, T., Jin, F., Xing, W., & Yu, S. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156455 · Cited by 3
mRNA medicine for cardiovascular disease
Zhou, Z., Chen, W., Yu, H., Tabas, I. A., Foo, R., & Tao, W. (2026) · Nature Cardiovascular Research · doi:10.1038/s44161-026-00804-8 · Cited by 6
Research progress in mRNA drug modification and delivery systems
Zhou, Z., & Li, X. (2023) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2023-0101 · Cited by 4
Research progress on mRNA drug delivery strategies in the nervous system
Yang, B., Liu, A., Li, X., & Miao, Z. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2530242 · Cited by 3
The transcription factor BCL11B drives NK cell cytotoxicity and antitumor activity
Kumar, A., Zhang, B., Baldys, A. M., Fischer, C., Lenvik, A. J., Felices, M., Davis, Z., Bendzick, L. E., Weis, A., Bryceson, Y. T., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf179 · Cited by 2
Pioneering next-generation mRNA therapeutics through molecular engineering and delivery optimization
Qi, L., Li, Z., Feng, Z., Liu, J., & Chen, X. S. (2025) · Materials Today · doi:10.1016/j.mattod.2025.08.023 · Cited by 3
mRNA therapy: A novel approach for retinal neurodegenerative diseases
Zhang, B., Tang, J., Zhang, Q., Qiu, Y., Cheng, Y., Yu, S., Liu, L., Xue, J., Liu, X., He, Q., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-01306 · Cited by 2
Unlocking the potential of mRNA nanomedicines for comprehensive fibrosis therapy
Yang, Y., Li, C., Xiong, W., Li, C., & Xiao, J. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102917 · Cited by 2
ADVANCES IN THE DEVELOPMENT OF MRNA-VACCINES
Golyak, N. S., Царенков, В. М., Sushinskaya, O. A., Sechko, O. G., & Malchenkova, S. S. (2025) · Vestnik Farmacii · doi:10.52540/2074-9457.2025.2.77 · Cited by 2
In vivo immune engineering via mRNA therapeutics: reprogramming the post-infarction cardiac microenvironment
Liu, Y. H., Liu, R., Meng, C., Li, J., Yang, K., Zhang, F., Xia, X., Ye, G., & Yuan, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1873905 · Cited by 2
The discovery and development of mRNA vaccines for the prevention of SARS-CoV-2 infection
Xue, V. W., Wong, S. C. C., Li, B., & Cho, W. C. S. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2218083 · Cited by 2
Purification of IVT mRNA by 5′ cap affinity chromatography
Du, B., & Lin, J. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1013 · Cited by 2
The potential of N2-modified cap analogues for precise genetic manipulation through mRNA engineering
Kurpiejewski, K., Stankiewicz-Drogoń, A., Piecyk, K., Rajkowska, E., Skrzypczyk, P., Geng, J., Darżynkiewicz, E., Grzela, R., & Jankowska‐Anyszka, M. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1269028 · Cited by 2
A Basic Method for Formulating mRNA-Lipid Nanoparticle Vaccines in the Lab
Jarzębska, N. T., Frei, J., Mellett, M., Kündig, T. M., Pascolo, S., & Reichmuth, A. M. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_11 · Cited by 2
Combinative workflow for mRNA vaccine development
Khanzode, R., Soni, G., Srivastava, S., Pawar, S. P., Wadapurkar, R. M., & Singh, A. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101766 · Cited by 2
Nanoparticle-Mediated Mucosal Vaccination: Harnessing Nucleic Acids for Immune Enhancement
Hussain, W., Chaman, S., Koser, N., Aun, S. M., Bibi, Z., Pirzadi, A. N., Hussain, J. S., Zubaria, Z., Nabi, G., Ullah, M. W., et al. (2024) · Current Microbiology · doi:10.1007/s00284-024-03803-9 · Cited by 2
The rational design of mRNA vaccine: From empirical method to artificial intelligence-based design
Hu, Y., Pu, C., Liu, B., & Zhang, L. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0478 · Cited by 2
Application of Mammalian Nudix Enzymes to Capped RNA Analysis
Łukaszewicz, M. (2024) · Pharmaceuticals · doi:10.3390/ph17091195 · Cited by 2
A tripartite cell-free translation system to study mammalian translation
Arendrup, F. S., Andersen, K. L., & Lund, A. H. (2025) · Nature Protocols · doi:10.1038/s41596-025-01155-7 · Cited by 2
Advancing Protein‐Coding RNA Engineering: From Structural Refinement to Biomedical Implementation
Lu, X., Li, S., Chi, Y., Lin, S., Yuan, H., Lin, Z., Xiao, Y., Yin, H., Zuo, X., Cheng, R., et al. (2025) · Biotechnology Journal · doi:10.1002/biot.70038 · Cited by 2
Lipid Nanoparticle-Encapsulated TALEN-Encoding mRNA Inactivates Hepatitis B Virus Replication in Cultured Cells and Transgenic Mice
Smith, T. S., Singh, P., Bhana, R., Kairuz, D., Bloom, K. M., Maepa, M. B., Ely, A., & Arbuthnot, P. B. (2025) · Viruses · doi:10.3390/v17081090 · Cited by 5
Streamlined DNA template preparation and co-transcriptional 5′ capped RNA synthesis enabled by solid-phase catalysisPreprint
García-Marquina, G., Zhang, A., Sproviero, M., Fang, Y., Gardner, A. F., Robb, G. B., Chan, S., & Xu, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.28.564520 · Cited by 2
Co-transcriptional capping using an RNA capping enzyme-T7 RNA polymerase fusion proteinPreprint
Chan, S., Tirole, L., Kneller, D. W., Kelley, T. M., Dai, N., & Robb, G. B. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.28.564488 · Cited by 2
mRNA vaccines for COVID-19
Sengupta, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91814-5.00007-6 · Cited by 1
Decoding trends in mRNA vaccine research: A comprehensive bibliometric study
Zhang, C., Wang, Y., Peng, J., Wen, X., Zhang, Y., Li, K., Du, H., & Hu, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2355037 · Cited by 1
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Hu, L., Berahovich, R., Huang, Y., Zhang, S., Sun, J., Liu, X., Zhou, H., Xu, S., Li, H., Golubovskaya, V., et al. (2025) · Journal of Visualized Experiments · doi:10.3791/67548 · Cited by 1
Optimization of In Vitro Transcription Reaction for mRNA Production Using Chromatographic At-Line Monitoring
Marušič, T., Seravalli, T. V., Celjar, A. M., Skok, J., & Sekirnik, R. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4742-4_9 · Cited by 1
In-process analytics for IVT mRNA manufacturing: from process understanding to advanced process control
Kim, N., Dong, E., Tschudi, K., & Camperi, J. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1800423 · Cited by 1
CJ-1: an optimized mRNA platform with enhanced protein expression and minimal immunogenicity for therapeutic applications
Kim, S., Jo, M. J., Jeong, M. S., Ha, M., Ham, Y., Hong, J., Kim, D., Yum, K., Yeon, J., Han, S., et al. (2026) · Gene Therapy · doi:10.1038/s41434-026-00606-4 · Cited by 1
Decoding Self vs. Non-Self: Alphavirus Cap0 Recognition and Immune Evasion
Faraj, S. E., & Filomatori, C. V. (2026) · Viruses · doi:10.3390/v18040439 · Cited by 2
Cross-protective efficacy of NA-based mRNA vaccine candidates against seasonal and avian influenza viruses
Kim, H., Lee, S., Cho, S., Shin, W., Lee, S., Park, S. M., Demirev, A. V., Lee, T., Kim, Y.-J., Kim, D., et al. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1791088 · Cited by 1
A Modular Mechanistic In Silico Model for In Vitro Transcription Process Yield and Product Quality Prediction
Wang, K., Choy, K., Reiser, E., Pei, J., Zheng, H., Dasgupta, A., Cheng, F., Dong, G., Mulukutla, B. C., Mannheimer, J., et al. (2026) · Biotechnology and Bioengineering · doi:10.1002/bit.70222 · Cited by 2
https://onco-hema.healthbooktimes.org/article/29047-mrna-vaccines-against-infectious-diseases-and-cancer?auth_token=GXnDwFXw-1WxSg9ozO7O
Meisel, A., & Pascolo, S. (2021) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2021.09.045 · Cited by 2
Ribonucleases for Sequencing and Characterization of RNA by LC–MS
Junior, I. R. C., Wolf, E. J., Yigit, E., & Chan, S. (2023) · RNA technologies · doi:10.1007/978-3-031-36390-0_27 · Cited by 1
The science of mRNA
Hillery, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28934-7.00003-0 · Cited by 1
The Eukaryotic mRNA Cap Structure
Pelletier, J., & Sonenberg, N. (2023) · Wiley eBooks · doi:10.1002/9780470015902.a0029559 · Cited by 1
mRNA Therapeutics and mRNA Vaccines
Itaka, K. (2021) · TRENDS IN THE SCIENCES · doi:10.5363/tits.26.10_38
Expanding the analytical toolbox for synthesis and characterization of ribonucleic acids
Strezsak, S. R. (2022) · doi:10.17760/d20429148
Synthetic mRNA Gene Therapies and Hepatotropic Non-viral Vectors for the Treatment of Chronic HBV Infections
Kairuz, D., Singh, P., Smith, T. S., Arbuthnot, P. B., Ely, A., & Bloom, K. M. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_8
A Possible Blue Print of Addressing mRNA Vaccine Efficacy
Li, B. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.6265
Design and Generation of MRNAS Encoding Conserved Regions of SARS-Cov-2 ORf1Ab for T Cell-Mediated Immune Activation
Nguyen, C. M., Luong, B. A., Tran, T. T., Nguyen, H., & Tran, L. S. (2023) · Future Virology · doi:10.2217/fvl-2023-0066
Trinucleotide mRNA cap analog N6-benzylated at the site of posttranscriptional m6 Am mark facilitates mRNA purification and confers superior translational properties in vitro and in vivoPreprint
Warmiński, M., Trepkowska, E., Śmietański, M., Sikorski, P. J., Baranowski, M. R., Bednarczyk, M., Kędzierska, H., Majewski, B., Mamot, A., Papiernik, D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.10.566532
Isolation of Double-Stranded RNAs by Lithium Chloride Fractionation
Chai, M., Ma, X., Chang, S., & Cheng, X. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3702-9_1
The P(III)‐Amidite Based Synthesis of Stable Isotope Labeled mRNA‐Cap‐Structures Enables their Sensitive Quantitation from Brain Tissue
Ripp, A., Krämer, M., Barth, V., Moser, P., Haas, T., Singh, J., Huck, T., Gleue, L., Friedland, K., Helm, M., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202414537
Purification of Enzymatically Active Xrn1 for Removal of Non-capped mRNAs from In Vitro Transcription Reactions and Evaluation of mRNA Decapping Status In Vivo
Drążkowska, K., Tomecki, R., & Tudek, A. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4176-7_7
COVID-19 Vaccine Manufacturing Processes: Making the Molecules to Solve the Pandemic
Romine, J. A. S., Kolodziej, S. A., Vetter, T., & Dux, M. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_8
Advances in the development of therapeutic mRNA vaccines for cancer therapy
Deng, K., Li, X., Liu, W., Liu, J., Wang, R., Yin, Y., & Zhang, C. Y. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0878

Authors: Henderson, J. M., Ujita, A., Hill, E., Yousif‐Rosales, S., Smith, C., Ko, N., McReynolds, T., Cabral, C. R., Escamilla‐Powers, J. R., & Houston, M. E.
Affiliations: TriLink BioTechnologies (United States) (US)
Corresponding author: Henderson, Jordana M.
ORCID: Henderson, Jordana M.
Hill, Elizabeth
Venue: Current Protocols
Publisher: Wiley
Published: 2021-02
Volume: 1
Issue: 2
Pages: e39-e39
ISSN: 2691-1299 (ISSN-L)
DOI: 10.1002/cpz1.39
OpenAlex: W3127832258
Cited by: 231
References: 38
Citations by year: 2026: 39 · 2025: 53 · 2024: 49 · 2023: 45 · 2022: 36 · 2021: 9
FWCI: 10.90
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Current Protocols (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Molecular Biology Techniques and Applications
Keywords: mRNA therapeutics, in vitro transcription, mRNA synthesis, mRNA purification, mRNA stability, mRNA vaccines, SARS-CoV-2
MeSH terms: Humans, RNA Cap Analogs, RNA, Messenger, Protein Biosynthesis, RNA Stability, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cap 1 Messenger RNA Synthesis with Co‐transcriptional CleanCap ® Analog by In Vitro Transcription

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks